Literature DB >> 32923142

Inflammation and lymphocyte infiltration are associated with shorter survival in patients with high-grade glioma.

Eliana Marinari1,2, Mathilde Allard1,2, Robin Gustave1,2, Valérie Widmer1,2, Géraldine Philippin1,2, Doron Merkler3, Petros Tsantoulis2,4, Valérie Dutoit1,2, Pierre-Yves Dietrich2,4.   

Abstract

Glioma represents a serious health burden in terms of morbidity and mortality. The prognostic significance of the lymphoid and myeloid infiltrates in glioma is not clearly determined. Moreover, the characterization of different leukocyte subsets in the tumor microenvironment relies mainly on immunohistochemistry observations, and data about their association with prognosis are contradictory. Here, we performed acomprehensive study of both the tumor-infiltrating and circulating immune compartments of patients with high-grade glioma. Nineteen tumor biopsies and 30 PBMC samples were analyzed by RNA sequencing. Validation was performed on The Cancer Genome Atlas (TCGA) RNA sequencing data from glioma and on additional 39 tumor biopsies analyzed by flow cytometry. We identified prognostic tumor and peripheral immune signatures, which associate increased inflammation, immune infiltration and activation with shorter overall survival in high-grade glioma patients. Importantly, we confirmed our observations by flow cytometry analysis and validated the tumor-signature using the TCGA dataset. In addition, both tumor genotype and grade associated with the degree of glioma immune infiltration. Unlike in the majority of cancers, lymphocyte infiltration at the tumor site is anegative prognostic factor in glioma, suggesting the ambivalent pro-tumorigenic role of immune responses in glioma.
© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.

Entities:  

Keywords:  Glioma; immune; lymphocyte; microenvironment; prognostic gene signature

Mesh:

Substances:

Year:  2020        PMID: 32923142      PMCID: PMC7458651          DOI: 10.1080/2162402X.2020.1779990

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  57 in total

1.  Role of IL-6 in the invasiveness and prognosis of glioma.

Authors:  Yongzhi Shan; Xin He; Wei Song; Dong Han; Jianxing Niu; Jianzhen Wang
Journal:  Int J Clin Exp Med       Date:  2015-06-15

2.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources.

Authors:  Da Wei Huang; Brad T Sherman; Richard A Lempicki
Journal:  Nat Protoc       Date:  2009       Impact factor: 13.491

3.  Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.

Authors:  Michael Weller; Nicholas Butowski; David D Tran; Lawrence D Recht; Michael Lim; Hal Hirte; Lynn Ashby; Laszlo Mechtler; Samuel A Goldlust; Fabio Iwamoto; Jan Drappatz; Donald M O'Rourke; Mark Wong; Mark G Hamilton; Gaetano Finocchiaro; James Perry; Wolfgang Wick; Jennifer Green; Yi He; Christopher D Turner; Michael J Yellin; Tibor Keler; Thomas A Davis; Roger Stupp; John H Sampson
Journal:  Lancet Oncol       Date:  2017-08-23       Impact factor: 41.316

Review 4.  The immune contexture in cancer prognosis and treatment.

Authors:  Wolf H Fridman; Laurence Zitvogel; Catherine Sautès-Fridman; Guido Kroemer
Journal:  Nat Rev Clin Oncol       Date:  2017-07-25       Impact factor: 66.675

5.  Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-β.

Authors:  Jennifer Lohr; Thomas Ratliff; Andrea Huppertz; Yingzi Ge; Christine Dictus; Rezvan Ahmadi; Stefan Grau; Nobuyoshi Hiraoka; Volker Eckstein; Rupert C Ecker; Thomas Korff; Andreas von Deimling; Andreas Unterberg; Philipp Beckhove; Christel Herold-Mende
Journal:  Clin Cancer Res       Date:  2011-04-08       Impact factor: 12.531

6.  The Molecular Signatures Database (MSigDB) hallmark gene set collection.

Authors:  Arthur Liberzon; Chet Birger; Helga Thorvaldsdóttir; Mahmoud Ghandi; Jill P Mesirov; Pablo Tamayo
Journal:  Cell Syst       Date:  2015-12-23       Impact factor: 10.304

7.  Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner.

Authors:  Rikke B Holmgaard; Dmitriy Zamarin; Yanyun Li; Billel Gasmi; David H Munn; James P Allison; Taha Merghoub; Jedd D Wolchok
Journal:  Cell Rep       Date:  2015-09-24       Impact factor: 9.423

8.  Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.

Authors:  Roger Stupp; Sophie Taillibert; Andrew Kanner; William Read; David Steinberg; Benoit Lhermitte; Steven Toms; Ahmed Idbaih; Manmeet S. Ahluwalia; Karen Fink; Francesco Di Meco; Frank Lieberman; Jay-Jiguang Zhu; Giuseppe Stragliotto; David Tran; Steven Brem; Andreas Hottinger; Eilon D. Kirson; Gitit Lavy-Shahaf; Uri Weinberg; Chae-Yong Kim; Sun-Ha Paek; Garth Nicholas; Jordi Bruna; Hal Hirte; Michael Weller; Yoram Palti; Monika E. Hegi; Zvi Ram
Journal:  JAMA       Date:  2017-12-19       Impact factor: 56.272

9.  Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.

Authors:  Timothy F Cloughesy; Aaron Y Mochizuki; Joey R Orpilla; Willy Hugo; Alexander H Lee; Tom B Davidson; Anthony C Wang; Benjamin M Ellingson; Julie A Rytlewski; Catherine M Sanders; Eric S Kawaguchi; Lin Du; Gang Li; William H Yong; Sarah C Gaffey; Adam L Cohen; Ingo K Mellinghoff; Eudocia Q Lee; David A Reardon; Barbara J O'Brien; Nicholas A Butowski; Phioanh L Nghiemphu; Jennifer L Clarke; Isabel C Arrillaga-Romany; Howard Colman; Thomas J Kaley; John F de Groot; Linda M Liau; Patrick Y Wen; Robert M Prins
Journal:  Nat Med       Date:  2019-02-11       Impact factor: 53.440

10.  Immune genes are associated with human glioblastoma pathology and patient survival.

Authors:  Elodie Vauléon; Avril Tony; Abderrahmane Hamlat; Amandine Etcheverry; Dan Cristian Chiforeanu; Philippe Menei; Jean Mosser; Véronique Quillien; Marc Aubry
Journal:  BMC Med Genomics       Date:  2012-09-14       Impact factor: 3.063

View more
  11 in total

Review 1.  The road-map for establishment of a prognostic molecular marker panel in glioma using liquid biopsy: current status and future directions.

Authors:  Richa Shrivastava; Puneet Gandhi; Ragini Gothalwal
Journal:  Clin Transl Oncol       Date:  2022-06-02       Impact factor: 3.340

2.  Immunologic Features in De Novo and Recurrent Glioblastoma Are Associated with Survival Outcomes.

Authors:  Cécile Alanio; Zev A Binder; Renee B Chang; MacLean P Nasrallah; E John Wherry; Donald M O'Rourke; Gregory L Beatty; Devora Delman; Joey H Li; Oliver Y Tang; Logan Y Zhang; Jiasi Vicky Zhang
Journal:  Cancer Immunol Res       Date:  2022-07-01       Impact factor: 12.020

3.  A Scoring System Based on Nutritional and Inflammatory Parameters to Predict the Efficacy of First-Line Chemotherapy and Survival Outcomes for De Novo Metastatic Nasopharyngeal Carcinoma.

Authors:  Wang-Zhong Li; Xin Hua; Shu-Hui Lv; Hu Liang; Guo-Ying Liu; Nian Lu; Wei-Xin Bei; Wei-Xiong Xia; Yan-Qun Xiang
Journal:  J Inflamm Res       Date:  2021-03-10

4.  Spatial immune heterogeneity of hypoxia-induced exhausted features in high-grade glioma.

Authors:  A-Reum Kim; Seong Jin Choi; Junsik Park; Minsuk Kwon; Tamrin Chowdhury; Hyeon Jong Yu; Sojin Kim; Ho Kang; Kyung-Min Kim; Su-Hyung Park; Chul-Kee Park; Eui-Cheol Shin
Journal:  Oncoimmunology       Date:  2022-01-12       Impact factor: 8.110

5.  A nomogram combining inflammatory markers and clinical factors predicts survival in patients with diffuse glioma.

Authors:  Ping Yan; Jian-Wen Li; Li-Gen Mo; Qian-Rong Huang
Journal:  Medicine (Baltimore)       Date:  2021-11-24       Impact factor: 1.817

6.  PODNL1 Methylation Serves as a Prognostic Biomarker and Associates with Immune Cell Infiltration and Immune Checkpoint Blockade Response in Lower-Grade Glioma.

Authors:  Humaira Noor; Ashraf Zaman; Charles Teo; Michael E Sughrue
Journal:  Int J Mol Sci       Date:  2021-11-22       Impact factor: 5.923

7.  Based on clinical Ki-67 expression and serum infiltrating lymphocytes related nomogram for predicting the diagnosis of glioma-grading.

Authors:  Zhi Zhang; Weiguo Gu; Mingbin Hu; Guohua Zhang; Feng Yu; Jinbiao Xu; Jianxiong Deng; Linlin Xu; Jinhong Mei; Chunliang Wang; Feng Qiu
Journal:  Front Oncol       Date:  2022-08-25       Impact factor: 5.738

Review 8.  Exploring glioblastoma stem cell heterogeneity: Immune microenvironment modulation and therapeutic opportunities.

Authors:  Amanda L Johnson; John Laterra; Hernando Lopez-Bertoni
Journal:  Front Oncol       Date:  2022-09-21       Impact factor: 5.738

9.  DIMEimmune: Robust estimation of infiltrating lymphocytes in CNS tumors from DNA methylation profiles.

Authors:  Sepehr Safaei; Malte Mohme; Judith Niesen; Ulrich Schüller; Michael Bockmayr
Journal:  Oncoimmunology       Date:  2021-06-17       Impact factor: 8.110

10.  Blood-Based Biomarkers for Glioma in the Context of Gliomagenesis: A Systematic Review.

Authors:  Hamza Ali; Romée Harting; Ralph de Vries; Meedie Ali; Thomas Wurdinger; Myron G Best
Journal:  Front Oncol       Date:  2021-06-04       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.